Related Experiment Video

Updated: Jun 20, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Thrombotic events in patients with cancer receiving antiangiogenesis agents

Maurizio Zangari1, Louis M Fink, Francesca Elice

  • 1University of Utah, Division of Hematology, Blood/Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA. maurizio.zangari@hsc.utah.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 26, 2009
PubMed

Insights

Angiogenesis inhibitors targeting tumor growth can cause bleeding and clotting. Research is needed to understand these risks and develop safe strategies for patients receiving these cancer therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Tumor-associated neoangiogenesis is a target for cancer drug development.
  • Several anti-angiogenic drugs are approved or in clinical trials.
  • These drugs can cause significant bleeding and thromboembolic events.

Purpose of the Study:

  • To review drug-associated hemostatic complications of anti-angiogenic therapies.
  • To discuss pathogenetic mechanisms and antithrombotic strategies.
  • To highlight the need for further research into safe prophylactic strategies.

Main Methods:

  • Literature analysis of thrombotic complications associated with anti-angiogenic drugs.
  • Review of known pathogenetic mechanisms.
  • Discussion of antithrombotic strategies.

Main Results:

  • Anti-angiogenic agents are associated with arterial and venous thromboembolism and hemorrhage.
  • Multiple approved agents include thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib, and sirolimus.
  • Hemostatic complications are significant toxicities requiring attention.

Conclusions:

  • Close attention to hemostatic complications during anti-angiogenic treatment is essential.
  • Further studies are required to elucidate pathophysiologic mechanisms.
  • Defining safe prophylactic strategies for these complications is necessary.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...